#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Chronic myeloid leukaemia – standardization of BCR-ABL1 transcript level monitoring in the Czech Republic


Authors: K. Zemanová 1;  H. Žižková 1;  T. Jurček 2;  D. Dvořáková 2;  J. Zach 1;  V. Polívková 1;  K. Vlčanová 1;  M. Divoká 3;  L. Křupková 3;  K. Hrochová 4;  M. Karas 5;  K. Machová Poláková 1
Authors‘ workplace: Oddělení molekulární genetiky, Ústav hematologie a krevní transfuze, Praha 1;  Centrum molekulární biologie a genové terapie, Interní hematologická a onkologická klinika, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity Brno 2;  Laboratoř molekulární biologie, Hemato-onkologická klinika, Fakultní nemocnice Olomouc LF UP v Olomouci 3;  Ústav klinické biochemie a diagnostiky, Fakultní nemocnice Hradec Králové 4;  Molekulárně genetická laboratoř, Hematologicko-onkologické oddělení, Fakultní nemocnice Plzeň 5
Published in: Transfuze Hematol. dnes,22, 2016, No. 1, p. 56-64.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Molecular monitoring of patients with chronic myeloid leukaemia has become a crucial part of therapeutic practice in the era of tyrosine kinase inhibitors. Introduction of BCR-ABL1 transcript quantification requires harmonization across laboratories worldwide. A network of BCR-ABL1 laboratories, that regularly undergo standardization and annual external quality controls, has been created in the Czech Republic since 2007. The progressive introduction of European LeukemiaNet recommendations for the management of CML and its molecular monitoring has increased in the increased reliability of BCR-ABL1 transcript level monitoring used for therapeutic decision making as well as the comparability of results from different laboratories.

KEY WORDS:
chronic myeloid leukaemia – BCR-ABL1 monitoring – standardization


Sources

1. Nowel PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960; 132: 1497.

2. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293.

3. Van Etten R, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989; 58(4): 669–678.

4. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P and Golde D. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994; 84(9): 2912–2918.

5. Cross NCP, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection fusion mRNAs in haematological disorders. Leukemia 1994; 8(1): 186–189.

6. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of CML. Blood 2013; 122: 872–874.

7. Silvy M, Mancini J, Thirion X, Sigaux F, Gabert J. Evaluation of real-time quantitative PCR machines for the monitoring of fusion gene transcripts using the Europe against cancer protocol. Leukemia 2005; 19: 2305–2307.

8. Muller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22: 96–102.

9. White H, Deprez L, Corbisier P, et al. A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR.Leukemia 2015; 29: 369–376.

10. Beillard E, Pallisgaard N, van der Velden VHJ, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using „real-time“ quantitative reverse- transcriptase polymerase chain reaction (RQ PCR) – a Europe Against Cancer Program. Leukemia 2003; 17: 2474–2486.

11. Cross NCP, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999–1003.

12. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

13. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular response to imatinib or interferon alfa plus cytarabin in newly diagnosed CML. N Engl J Med 2003, 349: 1423–1432.

14. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

15. Gabert J, Beillard E, van der Velden VHJ et al. Standardization and quality control studies of „real-time“ quantitative reverse polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

16. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with TKIs, Blood 2006; 108: 28–37.

17. Branford S, Cross NCP, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukemia. Leukemia 2006; 20: 1925–1930.

18. Müller MC, Cross NCP, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957–1963.

19. Branford S, Fletcher L, Cross CP, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials, Blood 2008; 112: 3330–3338.

20. Cross NCP, White HE, Müller MC, Saglio G and Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172–2175.

21. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with CML who have maintained complete molecular remission for at least two years (STIM trial). Lancet Oncol 2010; 11: 1029–1035.

22. Legros L, Rousselot P, Giraudier S, et al. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood 2012; 12(9): 1959–1960.

23. https://clinicaltrials.gov/ct2/show/NCT01596114.

24. Giles FJ, Rosti G, Ossenkoppele G, et al., Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed BCR-ABL1 positive CML in chronic phase: A European Clinical Initiative with EUTOS Collaboration for Standardization of Molecular Remission. Blood 2011; 118: 1186–1187.

25. https://clinicaltrials.gov/ct2/show/NCT01061177.

Labels
Haematology Internal medicine Clinical oncology

Article was published in

Transfusion and Haematology Today

Issue 1

2016 Issue 1

Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#